Aleena Banerji, MD, professor at Harvard Medical School and director of clinical care at the Center for Drug and Vaccine Allergy at Massachusetts General Hospital.

HAELO Phase 3: Lonvo-z Secondary Endpoints, QoL Data Detailed at EAACI

Lonvoguran ziclumeran (lonvo-z; Intellia Therapeutics), a one-time in vivo CRISPR gene-editing therapy for

, continued to demonstrate compelling efficacy across secondary endpoints in the phase 3 HAELO trial. The team presented new HAELO data in a late-breaking oral session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul and simultaneously published it in the 

 following the meeting, lead investigator Aleena Banerji, MD, professor at Harvard Medical School and director of clinical care at the Center for Drug and Vaccine Allergy at Massachusetts General Hospital, said the secondary endpoint data exceeded her expectations despite entering phase 3 with cautious optimism.

“Going into any phase 3 study [is] unpredictable [in terms of] what the efficacy is going to be,” Banerji said. “It was very exciting to see that not only did the data match what was being seen in the prior phase 1 and phase 2 study, but it really exceeded expectations."

Secondary Endpoints and HAE Attack Reductions

As previously reported, HAELO met its primary endpoint with an 87% reduction in mean monthly attacks in the lonvo-z arm versus placebo during the efficacy evaluation period from weeks 5 to 28.

 The newly disclosed secondary data built further on that result.

The monthly rate of moderate and severe attacks was reduced by 91% in patients receiving lonvo-z compared with placebo (0.11 vs. 1.23; 

 <.0001), and the monthly rate of attacks requiring on-demand treatment fell by 89% (0.19 vs. 1.79; 

Banerji called the absence of non-responders a particularly meaningful finding. Patient-level data demonstrated that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28.

"It's rare that we see that when you look across a lot of other trials or even outside of hereditary angioedema," Banerji said.

Quality of Life Improvements With Lonvo-Z

Patients receiving lonvo-z experienced a mean improvement of 17.04 points in the Angioedema Quality of Life (AE-QoL) total score compared with approximately 6.5 points in the placebo arm, a difference that exceeded the 6-point threshold considered clinically meaningful.

Banerji said that threshold context matters when interpreting the magnitude of that gain. “A 17-point change far exceeds what we believe is clinically meaningful," she noted. Patients in the trial reported being able to think differently about work, school, and travel—including activities like taking a cruise—without organizing their lives around the fear of an impending attack.

"It's the constant fear of that next attack and when it's going to occur," Banerji said. "Being able to change that and seeing this significant improvement in quality-of-life matching what we're seeing with efficacy is really promising for the real world."

The HAELO population included patients across a range of prior treatment histories, from those naive to long-term prophylaxis (LTP) to those who were attack-free on existing regimens. Notably, 20% of enrolled patients reported having complete disease control as their best response to prior long-term prophylaxis therapies and yet still chose to enroll.

Banerji addressed why patients already well-controlled on LTP would pursue an investigational gene editing therapy: the burden of treatment itself, including insurance approvals, supply management, and injection schedules.

“Just because they're doing well on long-term prophylaxis in terms of not having attacks or feeling that they are attack-free isn't the only aspect of hereditary angioedema,” she said.

All treatment-emergent adverse events (TEAEs) reported in the lonvo-z arm were mild or moderate, with no serious adverse events observed. The most common TEAEs exceeding placebo rates were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection.

Banerji said the safety monitoring focus centered on liver function, given the hepatic targeting mechanism of an in vivo CRISPR therapy. No transient or persistent elevations in liver function tests were observed, and infusion reactions resolved without interrupting dosing in any patient.

Plasma kallikrein levels decreased substantially by the first measurement at day 15, reached a steady state by week 5, and remained stable through the data cutoff of February 10, 2026, with all patients remaining LTP-free as of that date. 

Banerji said durability questions will require continued follow-up but drew confidence from the longer-term phase 1 and phase 2 data.

A rolling BLA submission for lonvo-z was initiated in April, and the company continues to anticipate regulatory approval and a US launch in the first half of 2027.

 When asked which patients she would prioritize, Banerji said her view has shifted toward broad candidacy.

"I think that every patient is eligible," she said. "The concerns are going to be around insurance and navigating some of those challenges, but in terms of talking to patients… we are going to help them understand that this is a newer treatment that's coming up on the market...and then go through all of the data, the efficacy, the safety concerns, the potential benefit, [and] risks. [We] help them think through this in a shared decision-making process so that they themselves can be the person that decides [if] is this the right treatment for them.”

Editor’s note: Reported disclosures for Banerji include CSL Behring and BioCryst Pharmaceuticals.

Intellia Therapeutics. Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema. June 13, 2026. 

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3

Derman C. Single-Dose Lonvo-z Cuts HAE Attacks by 87% in Phase 3 Trial, With Aleena Banerji, MD. HCPLive. Published May 11, 2026. 

https://www.hcplive.com/view/single-dose-lonvo-z-cuts-hae-attacks-87-phase-3-trial-aleena-banerji-md

Videos

Aleena Banerji, MD, reviews HAELO secondary data: 91% reduction in moderate/severe attacks, 17-point QoL gain, and zero non-responders for lonvo-z.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Bharat Saboo, MS, is the director of Prayas Diabetes Center.

Mitraa-T1D: AI-Driven Converastional Tool Improves T1D Diabetes Distress, Self-Care Behaviors

The usage of a digital conversational support tool resulted in improved glycemic control and self-care behaviors, as well as reduced diabetes distress, in adults with 

American Diabetes Association (ADA) Scientific Session 2026 

in New Orleans, Louisiana, by Bharat Saboo, MS, director of Prayas Diabetes Center in Indore, India, this study, titled Mitraa-T1D, evaluates the effectiveness of the Mitraa tool in managing a patient’s mental and emotional stress following diagnosis of and during treatment for T1D.

“We have a patchy healthcare system in our country, and it is not possible for us at any point in time to provide 24/7 continuous care and coverage to our patients,” Saboo told 

 in an exclusive interview. “We wanted to see if this device could improve patients’ distress scores, which is a very common problem with type 1 diabetes patients.”

Diabetes distress, unlike standard depressive symptoms, is directly linked to poor glycemic control and problematic self-care behaviors. Patients with either T1D or 

 are susceptible to elevated diabetes distress, and research has shown that it affects roughly 40 to 50% of adults and ≤60% of adolescents with T1D. Given these statistics, clinicians have concluded that diabetes distress represents a significant clinical problem.

To this end, Saboo and colleagues implemented Mitraa-T1D, an AI-driven digital support platform, among patients in India with T1D. A total of 308 adult patients with T1D – defined as HbA1c ≥7% - were enrolled to this 6-month, multicenter, parallel-group randomized controlled trial. These patients were randomly assigned in a 1:1 ratio to receive either usual care plus digital conversational support or usual care alone. Pregnant patients, as well as those with recent diabetic ketoacidosis, severe hypoglycemia, severe cognitive impairment, or advanced renal disease were excluded.

Saboo and colleagues assessed patients’ self-care behaviors via the Summary of Diabetes Self-Care Activities (SDSCA), and diabetes distress was monitored via the Diabetes Distress Scale. The study’s primary endpoint was change in HbA1c, while secondary outcomes included self-monitoring of blood glucose and physical activity.

HbA1c data were available for 292 of the 308 enrolled patients (94.8%), and mean age among these patients was 30.2 +/- 9.6 years. By the end of the study, mean HbA1c had decreased from 8.2 +/- 1% to 7.5 +/- 0.9% in the intervention group compared with 8.1 +/- 1.1% to 7.9 +/- 1% in the usual care group. This yielded a between-group difference of -0.5% (

 <.001). SDSCA scores also improved more in the intervention group (+1.3 vs +0.4; 

 <.001), and Diabetes Distress Scale scores declined by -0.8 in the intervention group compared to -0.3 in the usual care group (

 <.001). Mean self-monitoring of blood glucose frequency increased from 4 to 7 checks per day versus 4 to 5.

Saboo and colleagues concluded that the use of Mitraa was associated with these improvements in both physical and psychological symptoms of T1D.

Saboo also discussed the developmental process behind the device, pointing out that Mitraa was not a fully autonomous AI but instead a Large Language Model (LLM). The device is not designed to prescribe treatments or medications to patients – instead, Saboo emphasizes that it is simply programmed to serve as a conversational tool for patients unable to contact or visit their endocrinologists.

“The biggest advantage with Mitraa is that we have sandboxed it – it doesn’t give any treatment, it just acts as a buddy,” Saboo said. “It doesn’t prescribe insulin, it never adjusts the dose of insulin, it just directs the patient to connect with the doctor.”

Editors’ Note: Saboo reports no relevant disclosures.

Saboo B, Saboo S, Modi A, et al. Mitraa-T1D: A Multicenter Randomized Trial of a Digital Conversational Support Tool in Adults with Type 1 Diabetes. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Fisher L, Hessler D, Polonsky W, Strycker L, Masharani U, Peters A. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. J Diabetes Complications. 2016;30(6):1123-1128. 

Bharat Saboo, MS, discusses his recent study investigating the LLM device in improving both physical and psychological issues associated with T1D.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Samuel Shangwu Wu, PhD, is a professor and deputy director of the Health Informatics Institute at the University of South Florida.

Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D

Time to minimum residual C-peptide (TMRCP) is a clinically interpretable and statistically efficient endpoint for future studies in 

American Diabetes Association (ADA) Scientific Sessions 2026

 in New Orleans, Louisiana, by Samuel Shangwu Wu, PhD, professor and deputy director of the Health Informatics Institute at the University of South Florida, these data reflect a potentially more reliable endpoint for patients with T1D enrolled in clinical trials, utilizing all available longitudinal data to provide a stable and reliable efficacy measure.

Existing methods of measuring beta-cell function have historically proven difficult due to the challenges inherent in direct tissue sampling. Alternative methods, including insulin or C-peptide measurements, are similarly difficult due to changing levels of insulin resistance or cellular exhaustion.

“We feel that this time is more interpretable, and the patients will be easier to understand,” Wu told 

 in an exclusive interview. “And then we estimated that time with, of course, some extrapolation, and then we used these to compare whether their treatment is effective or not beyond the single time point in the measurement.”

TMRCP is defined as the time until C-peptide drops to a prespecified value, which represents the functional loss of beta-cell secretory capacity. Wu and colleagues estimated TMRCP by utilizing a nonlinear mixed-effects model and applying it to log-transformed mean area under curve (MAUC) C-peptide values collected via mixed-meal tolerance testing. The team states that this approach utilizes all available longitudinal measurements while accounting for repeated observations within individuals. Additionally, the strategy can manage variable visit schedules or incomplete follow-up from a given patient.

Wu and colleagues applied this estimation framework to 6 randomized, placebo-controlled, double-blind trials, the results of which were collected via TrialNet. Each trial investigated patients with recent-onset T1D, totaling 597 participants. Via Wilcoxon rank-sum tests on TMRCP estimates, the team highlighted the same 3 main treatments as effective as the original analyses.

Median TMRCP for the 3 effective treatments compared to placebo were 128 vs 84 days for Rituximab (

 = .03), and 110 vs 53 days for anti-thymocyte globulin (

 = .027). Differences were <4 days for the 3 non-effective treatments, including canakinumab, mycophenolate mofetil and daclizumab combined therapy, and glutamic acid decarboxylase.

Ultimately, the team concluded that, unlike fixed-time endpoints, TMRCP measures the loss of residual insulin secretion while providing patient-specific estimates to support robust treatment comparisons.

“For this TMRCP in the estimate, we used something like a random effect – in theory, we borrow the information from other patients to estimate each patient’s decline,” Wu said. “There is lots of variation between patients in terms of the rate of decline, but we borrow that information to estimate their slope and make it a little less variable.”

Editors’ Note: Wu reports disclosures with Vertex Pharmaceuticals and United HealthCare Services.

Wu S, Ding A, Krischer J, et al. Time to Minimal Residual C-Peptide as an Efficacy Measure in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Abstract presented at the American Diabetes Association (ADA) Scientific Sessions 2026, New Orleans, LA. June 5-8, 2026.

Hannon TS, Kahn SE, Utzschneider KM, et al. Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. 

Samuel Shangwu Wu, PhD, discusses his recent work evaluating TMRCP as an effective endpoint for future T1D trials.

Psoriasis-Associated Lung Disease and Clinical Pearls for Dermatologist

When Douglas DiRuggiero, PA-C, a physician assistant at Skin Cancer & Cosmetic Dermatology, joined a panel at the 

 in Colorodo alongside dermatologists Ted Rosen, MD (Baylor College of Medicine), Matthew Zirwas (Bexley Dermatology), MD, and Whitney High, MD (University of Colorado Anschutz), the goal was straightforward: leave clinicians with at least one piece of actionable information they could carry back into practice.

"If you've been in practice 10 years or more, you can sit in a 1-hour lecture, and if you come away with one pearl, it's worth the entire hour," DiRuggiero said.

The session, "Clinical Pearls for Optimizing Dermatologic Care," covered off-label, low-cost approaches to conditions that often resist standard treatment, including molluscum contagiosum and warts.

 For DiRuggiero, the standout moment came from Rosen, who described using a heating pad to help resolve widespread molluscum. The simplicity of the approach made an impression.

"We freeze these kids, and we put cantharidin on them. We write them medications, and they continue to proliferate," DiRuggiero said. "There are some really neat ways of treating things that may be simple and fast and effective."

DiRuggiero's own contribution centered on 

, specifically a literature update on what he described as the newest comorbidity dermatologists need to reckon with: lung disease. Drawing on a study published in November 2025 in Respiratory Medicine, he walked attendees through findings from roughly 250 patients at a single medical center who had undergone chest CT imaging and carried a diagnosis of moderate-to-severe psoriasis.

 Investigators found those patients were more likely to have significant pulmonary abnormalities, including ground-glass opacities, a pattern now being termed psoriasis-associated lung disease (PsO-LD).

DiRuggiero argued that the finding is a natural extension of what the field already knows about psoriasis as a systemic, multi-organ disease.

"We have known for years it affects the cardiovascular system, that it can lead to metabolic syndrome, fatty liver problems, joint [involvement]," he said. "Why would we think it would not potentially affect the lungs?"

The clinical implication is a new conversation dermatologists need to be having with patients: adding pulmonary risk to the already established counseling around cardiovascular disease, metabolic syndrome, and psoriatic arthritis.

Watch part 1 of our interview with DiRuggiero on his session “Prescribing with Precision: Antibiotic Stewardship in Dermatology” here:

Antibiotic Stewardship in Dermatology: A Call to Prescribe Less

Editor’s note: Reported disclosures include E.R. Squibb & Sons, L.L.C, GENZYME CORPORATION, Janssen Biotech, Regeneron Healthcare Solutions, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, ABBVIE., Galderma Laboratories, L.P., Boehringer Ingelheim Pharmaceuticals, Arcutis Biotherapeutics, and more.

DiRuggiero D. Clinical Pearls for Optimizing Dermatologic Care. Session presented at SDPA Summer 2026 from June 10 – 14.

Mitchell S, Peterson JA, Seely M, et al. Psoriasis-associated lung disease: A comprehensive review and case series. 

DiRuggiero on PsO-LD, a heating pad for molluscum, and why psoriasis counseling must now include pulmonary risk.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Psoriasis-Associated Lung Disease and Clinical Pearls for Dermatologist 

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

Shannon C. Trotter, DO, is a dermatologist and podcast host from Springfield, Ohio.

The Cost of Delay: How Prior Authorization Is Impacting Dermatology

 today, clinicians have access to an unprecedented array of biologics and targeted treatments designed to dramatically improving outcomes for individuals living with chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS).

However, according to 3 dermatologists interviewed by 

, gaining patients access to these drugs has evolved into a more and more complicated procedure. This, they and others in the field have noted, is due to prior authorization requirements, ‘step therapy’ protocols, and formulary restrictions caused by insurers and pharmacy benefit managers, also known as PBMs.

Prior authorization, the process by which health insurance plans go over and approve or deny various types of covered health services or medications, has evolved from an occasional administrative task into a routine part of practice management in dermatology.

 In this feature, the issues many clinicians have with the prior authorization process is explored, along with the potential need for future reforms.

Harrison Nguyen, MD, MBA, MPH, managing director of Harrison Dermatology & Research Group, was 1 such clinician who spoke with 

 about this complicated process as a substantial burden on both physicians and staff. While physicians may identify the most appropriate medication for a patient early in the visit, Nguyen highlighted the securing of a treatment’s approval as often requiring extensive paperwork, repeated communication with insurers, and dedicated personnel focused solely on navigating the authorization process.

Shannon Trotter, DO, known for her work with DOCS Dermatology Group, spoke with 

 about prior authorization, describing it as having long been a challenge in dermatology, though she highlighted the growing role of artificial intelligence (AI) in the process as both positive and negative. While AI tools can allow practices to better streamline submissions and diminish their own administrative workload, Trotter described insurers as also beginning to use similar technologies, creating what she described as an ongoing back-and-forth between providers and payers.

Outside of administrative burdens, all 3 of these clinicians emphasized the impact these barriers can have on patient care. Trotter pointed to step therapy requirements as a frequent source of delays, noting that patients may be required to try and fail therapies for months prior to gaining access to the medication their clinician originally recommended. During such time, a patient may continue experiencing symptoms that interfere with work, sleep, overall quality of life, or even becoming more debilitating.

Nguyen described formulary changes as also potentially forcing patients to switch from therapies that may already be working well. While some transitions occur without issue, he noted patients with conditions such as atopic dermatitis and HS can sometimes report disease worsening or loss of treatment response when required to shift between treatments for non-clinical reasons. In certain cases, Nguyen noted, interruptions in therapy can make future treatment far more challenging.

Matthew Zirwas, MD, a board-certified dermatologist at Dermatologists of Greater Columbus, spoke even more adamantly against prior authorization as a practice. Zirwas pointed to the growing number of available therapies as having intensified prior authorization challenges. He pointed to PBM rebate structures and limited transparency surrounding formulary decisions as key drivers of the issue, suggesting that treatment preferences often do not align with what clinicians believe is best for patients. Additionally, he noted his own view of the need for reforms that allow for incentives among PBMs to shift, as well as the need for more transparency.

Despite differences in emphasis, all 3 clinicians agreed that reform is needed. Proposed solutions included greater transparency around formulary and rebate decisions, streamlined authorization processes, improved peer-to-peer review systems, and reforms to step therapy requirements.

Overall, each of these 3 leaders in the field spoke in favor of a reduction of unnecessary barriers as helpful to ensure patients are given the right treatment at the right time, while nevertheless expressing the need to preserve access to the therapeutic advances known to have shaped the modern dermatologic landscape.

Disclosures: Trotter, Nguyen, and Zirwas had no relevant disclosures of note.

Amann ST, Shah ED, Wilson LJ. An Overview of the Challenging Process of Prior Authorization: Medical Necessity for a Better Way. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2362-2366. doi: 10.1016/j.cgh.2024.09.001. Epub 2024 Sep 18. PMID: 39303798; PMCID: PMC11604005.

Sharma SP, Russo A, Deering T, Fisher J, Lakkireddy D. Prior Authorization: Problems and Solutions. JACC Clin Electrophysiol. 2020 Jun;6(6):747-750. doi: 10.1016/j.jacep.2020.04.022. PMID: 32553230.

Sampathkumar G. Rethinking prior authorization: bridging clinical needs and administrative burdens. Am J Manag Care. 2026 Feb 1;32(2):e31-e33. doi: 10.37765/ajmc.2026.89883. PMID: 41759204.

Kyle MA, Song Z. The Consequences and Future of Prior-Authorization Reform. N Engl J Med. 2023 Jul 27;389(4):291-293. doi: 10.1056/NEJMp2304447. Epub 2023 Jul 22. PMID: 37486761; PMCID: PMC10676707.

Wang Y, Levy JF, Mattingly TJ 2nd, Anderson G. Prior Authorization and Associated Delays and Denials of Branded Medication Dispensation. JAMA Health Forum. 2026 Apr 3;7(4):e260760. doi: 10.1001/jamahealthforum.2026.0760. PMID: 41996105; PMCID: PMC13090851.


This video feature highlights the views of dermatologists on prior authorization, step therapy, and issues related to these processes.

Dermatologists write up to 10% of US antibiotics. At SDPA 2026, Douglas DiRuggiero, PA-C, explains why that must change and what to use instead.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Articles

Explore APAPP’s Las Vegas meeting with hands-on POCUS and airway labs, COPD and ILD bootcamps, AI updates, and new therapy insights.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

What to Expect at the 2026 APAPP National Conference

Brian E. Lacy, PhD, MD, a board-certified gastroenterologist at the Mayo Clinic in Jacksonville.

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

Food Allergy

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Strategic Alliance Partnership

When Abdominal Pain Is Actually a Food Allergy: A GI Workup

Aboul-Fettouh walks through the clinical and patient-centered factors that move a patient from localized, monitored disease to systemic JAK-inhibitor therapy, emphasizing that SALT score thresholds from clinical trials do not define the real-world trigger for treatment escalation.


Video Series

Identifying Patients for Systemic Therapy: Beyond

Elizabeth A. Kiracofe, MD, is a board-certified dermatologist and the founder of Airia Comprehensive Dermatology, located in downtown Chicago's Fulton Market District, where she practices medical, surgical, and cosmetic dermatology.

Podcasts

This discussion centers on patient empowerment, shared decision-making, and advancing equitable dermatologic care for those with skin of color.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Patient Power—Voices Driving Change in Skin of Color Care

Aboul-Fettouh addresses a persistent misconception among referring clinicians-that AA hair loss will resolve spontaneously-and makes the case for earlier referral and treatment initiation to preserve the greatest opportunity for hair regrowth.


What Referring Physicians Should Know: Avoiding the "Wait and See" Approach

Experts explore why FCS remains one of the most emotionally and clinically challenging lipid disorders despite decades of management effort.

Clinical Burden and Unmet Need in Familial Chylomicronemia Syndrome

Oksana Hamidi, DO, is an associate professor in the division of endocrinology and metabolism at UT Southwestern Medical Center

Two-year CAHtalyst data show crinecerfont sustained glucocorticoid reduction and improved metabolic outcomes in classic CAH.


Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Crinecerfont Sustains Glucocorticoid Reduction, Improves Cardiometabolic Outcomes in Classic CAH

Elena Christofides, MD, is the chief executive officer of Endocrinology Associates, the scientific and medical advisor for Sparrow Pharmaceuticals, and a clinical associate professor at the Ohio University Heritage College of Osteopathic Medicine.

Elena Christofides, MD, discusses her recent analysis of patients with ulcerative colitis receiving corticosteroids.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

HPA-Axis Assessment Allows for Improved Corticosteroid Response Analysis

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

Latest News

HAELO Phase 3: Lonvo-z Secondary Endpoints, QoL Data Detailed at EAACI

Mitraa-T1D: AI-Driven Converastional Tool Improves T1D Diabetes Distress, Self-Care Behaviors

Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D

Psoriasis-Associated Lung Disease and Clinical Pearls for Dermatologist

The Cost of Delay: How Prior Authorization Is Impacting Dermatology